Candidate Compounds Covid19

Version vom 2. Juli 2020, 14:10 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.

• reviews on covid drug development
• scouting ideas

• Patients on biologicals
• HMGB1, RAGE
• pre-Interleukin 6
• post-Interleukin 6
• pre-TNFalpha
• post-TNFalpha
• pre-Interleukin 17
• post-Interleukin 17
• pre-Interleukin 1
• post-Interleukin 1
• Inflammasome colchicine
• Methotrexate
• other anti-inflammatory
• NK-kappaB
• STAT 3
• JAK Janus Kinase
• Corticosteroids
• Cytokine absorbers
• Target Complement system
• Target Extracellular traps
• TGF beta
• Anticoagulant in covid19
• Antioxidants
• Stem cells
• MDSC cells
• Interferons

• other single compounds
• Retargeted single compounds
• Hydroxychloroquine
• Target ACE2, Spike protein
• Target TMPRSS2, Spike protein any other covid targed herein
• other antiviral compounds
• AV Remdesivir
• AV Lopinavir
• AV Ivermectin
• AV Arabidol
• AV Favipiravir

• Vitamin D
• Anorganic nutrients Magnesium
• Anorganic nutrients Selenium
• Anorganic nutrients Zinc
• Nutrition, general
• Exercise, Vibration

• Traditional Chinese Medicine
• Natural compounds

• Statins
• Antidiabetic compounds, any
• RSP - On RAS drugs

• Reconvalescent blood products, Passive vaccine
• Plasmapheresis

• Immunodeviation e.g. by adjuvants or other vaccinations
• Radiation therapy
• Phototherapy
• Active vaccine

-rest-

32458400 2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.
32401611 2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.
32413736 2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.
32534188 2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.
32531935 2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.
32384202 2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.
32315803 2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.
32519894 2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.
32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.
32399093 2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.
32532623 2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
32401215 2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.
32468385 2020. Musings on the current state of COVID-19 modeling and reporting.
32523144 2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.
32516380 2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.
32390307 2020. Practical tips for using masks in the COVID-19 pandemic.
32358890 2020. Cutaneous side-effects of the potential COVID-19 drugs.
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.
32406749 2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.
32535509 2020. COVID-19, interferons, and depression: A commentary.
32496248 2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.
32496246 2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.
32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.
32423974 2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?
32475104 2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.
32418757 2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?
32505040 2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.
32472939 2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.
32491981 2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.
32487283 2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.
32460209 2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.
32512579 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.
32116200 2020. COVID-19: Perspectives on the Potential Novel Global Threat.
32463459 2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.
32498081 2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
32464736 2020. A simulation training course for family medicine residents in China managing COVID-19.
32442317 2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).
32403134 2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
32407551 2020. Interrogation of the safety and efficacy of home-use light-based devices.
32429705 2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.
32510719 2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
32500633 2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32380052 2020. Granulocyte-targeted therapies for airway diseases
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro

009

32535032 2020. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.
32435607 2020. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.
32423449 2020. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
32493510 2020. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
32405423 2020. Minimum costs to manufacture new treatments for COVID-19.
32405422 2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.
32405421 2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
32401274 2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.
32392282 2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
32501511 2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
32530438 2020. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.
32459647 2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.
32384188 2020. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.
32533592 2020. Pharmacist's perspective on HCQ treatment of COVID-19.
32460458 2020. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
32401715 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
32401712 2020. Interferon beta-1b for COVID-19.
32410758 2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.
32450109 2020. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?
32464115 2020. Caution against corticosteroid-based COVID-19 treatment.
32473680 2020. The starting line for COVID-19 vaccine development.
32450106 2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
32445630 2020. Vitamin-D and COVID-19: do deficient risk a poorer outcome?
32450054 2020. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
32473139 2020. Death threats after a trial on chloroquine for COVID-19.
32518920 2020. Caution and clarity required in the use of chloroquine for COVID-19.
32501454 2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
32518419 2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
32528040 2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
32535078 2020. Vaccination strategies to combat novel corona virus SARS-CoV-2.
32535080 2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
32497632 2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
32454157 2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
32450171 2020. Coronaviruses pandemics: Can neutralizing antibodies help?
32450166 2020. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.
32422305 2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.
32418894 2020. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
32478465 2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
32532461 2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.
32425245 2020. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia cientifica concluyente.
32416415 2020. Etoposide-based therapy for severe forms of COVID-19.
32516655 2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.
32504923 2020. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.
32485316 2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
32498007 2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.
32492562 2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
32480250 2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.
32464491 2020. Selenium supplementation in the prevention of coronavirus infections (COVID-19).
32526511 2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.
32473509 2020. Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.
32470789 2020. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.
32534175 2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.
32464494 2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.
32526507 2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.
32464493 2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.
32464492 2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?
32460208 2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
32425307 2020. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.
32425306 2020. Protective potential of Expectorants against COVID-19.
32425303 2020. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
32428811 2020. Exercise as medicine for COVID-19: An ACE in the hole?
32416408 2020. As a potential treatment of COVID-19: Montelukast.
32413699 2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
32531538 2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
32531537 2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?
32516733 2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.
32535456 2020. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana.
32534337 2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.
32505075 2020. Fighting against frailty and sarcopenia - As well as COVID-19?
32505072 2020. COVID-19 and picotechnology: Potential opportunities.
32505069 2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.
32400020 2020. COVID-19 and implications for thiopurine use.
32395220 2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
32470350 2020. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.
32497535 2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
32418885 2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
32473390 2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?
32437926 2020. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
32445881 2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.
32442649 2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.
32533920 2020. The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2.
32404512 2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
32445440 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32445439 2020. Surgery Scheduling in a Crisis.
32433465 2020. Immunogenicity of a DNA vaccine candidate for COVID-19.
32529545 2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?
32499636 2020. COVID-19 vaccines: neutralizing antibodies and the alum advantage.
32533109 2020. Passive antibody therapy in COVID-19.
32393823 2020. BCG-induced trained immunity: can it offer protection against COVID-19?
32462282 2020. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
32451597 2020. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.
32430617 2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).
32350818 2020. Chloroquine-induced QTc prolongation in COVID-19 patients.
32342609 2020. The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.
32383751 2020. Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.
32528732 2020. Universal coronavirus vaccines: the time to start is now.
32509338 2020. Certainty of success: three critical parameters in coronavirus vaccine development.
32521760 2020. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.
32532069 2020. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?
32519174 2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?
32528623 2020. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?
32456404 2020. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.
32431755 2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.
32451736 2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.
32454586 2020. Demand for potentially hazardous COVID-19 treatments.
32454583 2020. ICER releases pricing models for potential COVID-19 treatments.
32473310 2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
32445956 2020. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).
32445955 2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"
32442720 2020. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
32430287 2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.
32430286 2020. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?

32405226 2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.
32438037 2020. Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis.
32438034 2020. Does lopinavir really inhibit SARS-CoV-2?
32407959 2020. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
32502640 2020. Optimising effectiveness of health care and value of clinical trials in the COVID -19 outbreak.
32470470 2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.
32442437 2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
32437972 2020. COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract.
32425361 2020. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.
32493609 2020. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?
32519302 2020. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
32415971 2020. Use of statins in patients with COVID-19.
32415962 2020. Reply: Use of statins in patients with COVID-19.
32437821 2020. Radiation therapy for COVID-19 pneumopathy.
32437820 2020. Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).
32413531 2020. Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable.
32522574 2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
32514354 2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.
32394513 2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
32426002 2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.
32426001 2020. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes.
32395001 2020. Evidencia viva como respuesta a las controversias en el uso de antimalaricos en COVID-19.
32414660 2020. Exercising in times of COVID-19: what do experts recommend doing within four walls?
32491104 2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.
32501367 2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.
32418114 2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
32518317 2020. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.
32413619 2020. beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.
32513867 2020. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
32434945 2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
32404477 2020. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.
32385228 2020. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.
32467561 2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
32460839 2020. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.
32526079 2020. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.
32388805 2020. Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence?
32394099 2020. Low-dose radiotherapy for SARS-CoV-2 pneumonia.
32412544 2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme.
32528195 2020. Broad beans (Vicia faba) and the potential to protect from COVID-19 coronavirus infection.
32528194 2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.
32436460 2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
32436445 2020. Potential specific therapies in COVID-19.
32483428 2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.
32473812 2020. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.
32418732 2020. Chloroquine and hydroxychloroquine during pregnancy: What do we know?
32457932 2020. Chloroquine, hydroxychloroquine and COVID-19.
32487513 2020. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.
32532691 2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
32467007 2020. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.
32425645 2020. Use of convalescent plasma in COVID-19 patients in China.
32406985 2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
32473994 2020. Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.
32485391 2020. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?
32360423 2020. Malaria prophylaxis approach during COVID-19 pandemic.
32471655 2020. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.
32454984 2020. Battling COVID-19: using old weapons for a new enemy.
32376108 2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.
32387011 2020. Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.
32418794 2020. A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.
32526960 2020. Immunoinformatics and Structural Analysis for Identification of Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets.
32531955 2020. Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.
32236815 2020. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.
32524253 2020. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
32530808 2020. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.
32531236 2020. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
32532094 2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
32532085 2020. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
32426090 2020. COVID-19, asthma, and biologic therapies: What we need to know.
32417996 2020. BCG versus COVID-19: impact on urology.
32514854 2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.

PMC searches were done at moremed.org

32581256 2020. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
32555446 2020. Overview of therapeutic drug research for COVID-19 in China.
32544884 2020. De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2.
32574894 2020. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
32583087 2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.
32551892 2020. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
32543882 2020. Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy.
32571831 2020. IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY.
32575554 2020. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.
32562705 2020. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
32557214 2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.
32586336 2020. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19.
32554525 2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
32572174 2020. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.
32546835 2020. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
32557011 2020. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.
32492407 2020. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.
32546764 2020. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.
32541865 2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
32588163 2020. Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.
32585295 2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
32564213 2020. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.
32564212 2020. Comment on "Colchicine may not be effective in COVID-19 infection; it may even be harmful?"
32556936 2020. Colchicine as a possible therapeutic option in COVID-19 infection.
32548723 2020. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.
32542396 2020. Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy.
32593060 2020. Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.
32558354 2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.
32552848 2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.
32552832 2020. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.
32572376 2020. Literature-based review of the drugs used for the treatment of COVID-19.
32578027 2020. A Rapid Advice Guideline for the Prevention of Novel Coronavirus Through Nutritional Intervention.
32562159 2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
32542964 2020. Treatment of Covid19 - Repurposing drugs commonly used in dermatology.
32542893 2020. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.
32537890 2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.
32592841 2020. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.
32581194 2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
32554953 2020. Can mesenchymal stem cell therapy be the interim management of COVID-19?
32592866 2020. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine.
32574699 2020. Discovering small-molecule therapeutics against SARS-CoV-2.
32574697 2020. Current and future therapeutical approaches for COVID-19.
32569833 2020. Exportin 1 inhibition as antiviral therapy.
32546018 2020. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
32578156 2020. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
32592145 2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
32574958 2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.
32573433 2020. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.
32569446 2020. Can artificial intelligence identify effective COVID-19 therapies?
32579067 2020. In Vivo Expressed Biologics for Infectious Disease Prophylaxis: Rapid Delivery of DNA-Based Antiviral Antibodies.
32562594 2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.
32548679 2020. Calling for an exponential escalation scheme in vaccine development for COVID-19.
32591957 2020. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.
32561291 2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?
32554535 2020. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond.
32589055 2020. Vesicular drug-delivery systems as theranostics in COVID-19.
32564623 2020. Tackling SARS-CoV-2: proposed targets and repurposed drugs.
32578073 2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.
32577840 2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.
32544304 2020. Antiretroviral HIV drugs in COVID-19 research: promises and risks. An opinion piece.
32591003 2020. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery.
32546029 2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
32565362 2020. Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissues.
32588335 2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.
32557206 2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.
32582401 2020. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.
32582400 2020. Steps towards COVID-19 suppression.
32585611 2020. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.
32565195 2020. Chloroquine cardiac effects and toxicity.A short update.
32585284 2020. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.
32579907 2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.
32585194 2020. Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence.
32592113 2020. Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.
32564289 2020. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment.
32572516 2020. Remdesivir bei Patienten mit COVID-19.
32588377 2020. Corticosteroids in diabetes patients infected with COVID-19.
32583443 2020. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors-authors' reply.
32578215 2020. Could Anti-Tubercular Vaccination Protect Against Covid-19 Infection?
32552021 2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.
32579022 2020. Lung Mechanics in COVID-19 Resemble RDS not ARDS: Could Surfactant be a Treatment?
32579020 2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?
32551560 2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
32585180 2020. Use of inhaled corticosteroids in asthma and COVID-19 : Keep calm and carry on.
32539520 2020. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
32561608 2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.
32574109 2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.
32589165 2020. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
32551883 2020. COVID-19 and the Drug Repurposing Tsunami.
32573724 2020. Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion.
32559767 2020. Use of Convalescent Plasma in Hospitalized Patients with Covid-19 - Case Series.
32576548 2020. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint.
32546467 2020. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds.
32540958 2020. Hydroxychloroquine for covid-19: the end of the line?
32556143 2020. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital.
32548616 2020. Corticosteroids in patients with COVID-19: what about the control group?
32588427 2020. QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection.
32589775 2020. Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects.
32552642 2020. Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19.
32584431 2020. Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.
32562762 2020. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
32592507 2020. Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.
32588937 2020. Adjustments in analyses of vitamin D status, allowing for vitamin D determinants, for Covid-19 risks.
32559771 2020. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.
32588530 2020. RNA to the rescue: RNA is one of the most promising targets for drug development given its wide variety of uses.
32567239 2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.
32543297 2020. Why do SARS-COV vaccines not exist? The pharma scientific intelligence and business model must be revisited!
32574081 2020. Can nanotechnology help in the fight against COVID-19?
32552044 2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.
32576053 2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.
32553760 2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.
32553757 2020. Aminosalicylates and COVID-19: Facts or Coincidences?
32554621 2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.

32557648 2020. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.
32557541 2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
32561274 2020. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
32567262 2020. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
32537956 2020. Uncertainty about the Efficacy of Remdesivir on COVID-19.
32539378 2020. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.
32562701 2020. Apelin-potential therapy for COVID-19?
32588188 2020. Comment on "Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?"
32565096 2020. Anticipating SARS-CoV-2 Vaccine Testing, Licensure, and Recommendations for Use.
32543196 2020. Repositioning of 8565 Existing Drugs for COVID-19.
32586380 2020. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19).
32591466 2020. SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds.
32589146 2020. Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir.
32536150 2020. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
32553190 2020. Appropriate selection of convalescent plasma donors for COVID-19.
32555367 2020. Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.
32555296 2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
32553928 2020. Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.
32561657 2020. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
32590324 2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.
32575019 2020. Pirfenidone: A novel hypothetical treatment for COVID-19.
32558640 2020. Cibler la protease majeure du SARS-CoV-2 pour fabriquer un medicament efficace contre ce coronavirus.
32590819 2020. Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study.
32574789 2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
32570850 2020. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.
32546125 2020. Erythropoietin as candidate for supportive treatment of severe COVID-19.
32560203 2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.
32551679 2020. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity.
32557405 2020. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences.
32576980 2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.
32572246 2020. Preclinical data from SARS-CoV-2 mRNA vaccine.
32555401 2020. Optimizing safety surveillance for COVID-19 vaccines.
32587103 2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
32590117 2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.
32405159 2020. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
32564413 2020. Is 0.5% Hydrogen Peroxide Effective against SARS-CoV-2?
32587806 2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.
32590099 2020. The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19.
32569819 2020. Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients.
32565309 2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
32592716 2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
32562826 2020. Therapeutic potential of resveratrol against emerging respiratory viral infections.
32542785 2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.
32592911 2020. Does PDT have potential in the treatment of COVID 19 patients?
32585401 2020. Optical theranostics and treatment dosimetry for COVID-19 lung complications: towards increasing the survival rate of vulnerable populations.
32585400 2020. Ultraviolet-based biophotonic technologies for control and prevention of COVID-19, SARS and related disorders.
32561979 2020. Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules.
32575476 2020. Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells.
32569450 2020. Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective.
32570995 2020. Short-Term Dexamethasone in Sars-CoV-2 Patients.
32552811 2020. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha7 receptor: role of nAChR alpha7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation.
32558034 2020. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19.
32557955 2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.
32571730 2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.
32579014 2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.
32579012 2020. COVID-19. Immunothrombosis and the gastrointestinal tract.
32558210 2020. Clearance of chloroquine and hydroxychloroquine by the Seraph(R) 100 Microbind(R) Affinity blood filter - approved for the treatment of COVID-19 patients.
32568026 2020. Targeting infectious Coronavirus Disease 2019 (COVID-19) with Artificial Intelligence (AI) applications: Evidence based opinion.
32593196 2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.
32579043 2020. Is there any supportive evidence for low dose radiotherapy for COVID-19 pneumonia?
32589449 2020. Current State of Research About Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19): A Scoping Review.
32579021 2020. Meditation and Yoga Practices as Potential Adjunctive Treatment of SARS-CoV-2 Infection and COVID-19: A Brief Overview of Key Subjects.
32591771 2020. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.
32556272 2020. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.
32586154 2020. Montelukast's ability to fight COVID-19 infection.
32583729 2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.
32579065 2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.
32579064 2020. In-silico investigation of phytochemicals from Asparagus racemosus as plausible antiviral agent in COVID-19.
32579061 2020. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).
32579059 2020. Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets.
32573355 2020. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.
32573351 2020. Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach.
32571168 2020. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
32568620 2020. Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico approach.
32568618 2020. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.
32568613 2020. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.
32568013 2020. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2.
32568012 2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.
32567995 2020. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
32567989 2020. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2.
32567979 2020. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.
32567501 2020. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.
32567487 2020. nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine.
32568969 2020. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.
32579707 2020. Clinical pharmacology considerations for developing small molecule treatments for COVID-19.
32571115 2020. Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice.
32538738 2020. Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.
32584243 2020. Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History.
32591393 2020. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
32559452 2020. Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?
32559419 2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.
32546047 2020. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic.
32574572 2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.
32579258 2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.
32578354 2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.
32554811 2020. Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir.
32588453 2020. Covid-19 and Thymoquinone: Connecting the Dots.
32552307 2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.
32564047 2020. Chloroquine in controlling biological infections.
32569363 2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study.
32584474 2020. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
32568376 2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.
32556278 2020. Real-life experience of tocilizumab use in COVID-19 patients.
32543892 2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
32590699 2020. ACTH 1-24 and other melanocortins for COVID-19 treatment.
32585765 2020. A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient.
32573990 2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab.
32584762 2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
32591367 2020. Is the production of a Covid-19 vaccine using transformed Pasteurella plausible?
32542847 2020. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.